Clinical Trial Update: A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and tolerability of GW642444 in Chronic Obstructive Pulmonary Disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GW642444 (GW642444)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2018-02-22